Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down – Time to Sell?

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY) gapped down before the market opened on Wednesday . The stock had previously closed at $14.21, but opened at $13.51. Astellas Pharma shares last traded at $13.40, with a volume of 3,399 shares.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ALPMY shares. Smbc Nikko Sec. upgraded shares of Astellas Pharma to a “hold” rating in a research note on Monday, February 16th. Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday. Finally, Jefferies Financial Group raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Astellas Pharma currently has an average rating of “Hold”.

Astellas Pharma Stock Performance

The company’s fifty day moving average is $15.35 and its 200 day moving average is $14.48. The company has a market capitalization of $24.23 billion, a P/E ratio of 12.47 and a beta of 0.08. The company has a current ratio of 1.09, a quick ratio of 0.84 and a debt-to-equity ratio of 0.23.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings data on Monday, April 27th. The company reported $0.33 EPS for the quarter, topping the consensus estimate of $0.19 by $0.14. The company had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.28 billion. Astellas Pharma had a net margin of 13.66% and a return on equity of 24.19%. As a group, equities analysts anticipate that Astellas Pharma Inc. will post 1.29 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).